Business Wire

NY-DRIVEWEALTH

Share
DriveWealth Celebrated as Category Leader with Top-Tier Industry Accolades from Deloitte, Forbes, CB Insights, More, During Landmark Year

DriveWealth, LLC, a global fintech investment rail and pioneer in fractional investing, today announced that following its milestone year of rapid global expansion, customer growth, and product innovation, the company has been recognized for its achievements as the category leader that is redefining investing through 10 of the most prominent industry awards. Each of these lists recognize the world’s most innovative and influential businesses and include:

  • Product awards: DriveWealth recently partnered with Adaptive Financial Consulting to build a new proprietary order management system (OMS) to address increased demand in its retail brokerage business. This high-throughput, low-latency OMS, which leverages Aeron technology, was recognized as 2022’s Best Collaboration/Alliance Initiative by Waters Technology’s American Financial Technology Awards.

“Our solutions are transforming the investing landscape and we’re honored to see such positive industry recognition for our work,” said Bob Cortright, Founder of DriveWealth. “DriveWealth’s significant global growth this year can be directly attributed to the flexible scalability and customization of our platform’s APIs. We look forward to remaining the primary industry choice for fintechs who are looking to empower their customers with innovative investing solutions worldwide.”

These industry accolades built upon a number of milestones that DriveWealth achieved in 2022, including:

  • Grew its global footprint: DriveWealth built upon key partnerships in Europe (Bank of Georgia) and Asia Pacific (Toss Securities), in addition to launching new partnerships in underserved markets such as Africa (Chipper Cash) and Latin America (Sproutfi) to expand affordable access to investing. In addition to notable new partnerships, DriveWealth expanded its global footprint by establishing presences in Singapore, London, Dublin, Lithuania, and Brazil to support partners and retail investors globally.
  • Bolstered its innovative suite of services: DriveWealth’s Fracker®, its proprietary OMS that has reinvented the retail investing experience for millions worldwide, was granted a patent by the U.S. Patent and Trademark Office. In addition to launching two wholly-owned subsidiaries, DriveDigital and DriveLiquidity, to offer cryptocurrency capabilities to partners and their retail investors, the company launched its Developer Dashboard to enable developers to gain free, instant access to the same resilient and scalable APIs that DriveWealth’s partners access in a sandbox environment. Finally, the firm expanded its DriveAdvisory platform, a technology infrastructure solution that empowers partners to fully integrate financial advisory products into their existing apps.

DriveWealth anticipates significant opportunities for growth in 2023, supported by results included in its proprietary DriveTrends report, which showed that digital trading became increasingly popular this year among global Millennials even amid 2022 market lows – a trend expected to continue into 2023. The study analyzed data from more than 12 million investors worldwide who trade fractional shares of U.S. equities through DriveWealth’s network of 100+ global partners, including MoneyLion, Revolut, Grupo Bursátil Mexicano (GBM), and Goalsetter, among others.

About DriveWealth

DriveWealth, a global fintech investment rail and pioneer of fractional equities trading, is a visionary technology company that empowers more than 100 partners around the world to engage their customers by placing the markets in the palm of their hands. We believe the future is fractional, transactional and mobile. Every mobile device should be a gateway to accessing investing and savings products, services, advice, and assistance for global citizens of all ages, wealth stages, and levels of financial expertise. DriveWealth’s consultative support and cloud-based, modern technology platform allow partners to seamlessly offer branded investing experiences to drive customer acquisition, loyalty, retention, and revenue growth. For more information, please visit drivewealth.com or connect with us on Twitter @DriveWealth or on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005077/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye